LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

LogicBio Therapeutics, a clinical-stage genetic medicine company based in Lexington, MA, announced that its CEO, Fred Chereau, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET on September 13. The company focuses on gene editing and delivery platforms, including GeneRide for precise gene insertion and sAAVy for optimizing gene delivery.

LEXINGTON, Mass., Sept. 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available at 7:00 a.m. ET on Monday, September 13, 2021.

About LogicBio Therapeutics 
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company's gene editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

Investor Contacts: 
Laurence Watts
Gilmartin Group
(619) 916-7620
laurence@gilmartinir.com

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Media Contacts:
Adam Daley
Berry & Company Public Relations
W:212-253-8881
C: 614-580-2048
adaley@berrypr.com

Jenna Urban
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com

 

View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301373192.html

SOURCE LogicBio Therapeutics, Inc.

FAQ

When is LogicBio's conference presentation scheduled?

LogicBio's conference presentation is scheduled for September 13, 2021, at 7:00 a.m. ET.

What is the H.C. Wainwright conference?

The H.C. Wainwright conference is an annual global investment event where companies present their business overviews and updates.

What platforms does LogicBio specialize in?

LogicBio specializes in gene editing and delivery platforms, specifically GeneRide and sAAVy.

Where is LogicBio Therapeutics located?

LogicBio Therapeutics is based in Lexington, Massachusetts.

What is the stock symbol for LogicBio Therapeutics?

The stock symbol for LogicBio Therapeutics is LOGC.